Human
Drugs
The most complex and highest-stakes FDA category. Covers the complete drug development lifecycle — from Investigational New Drug (IND) through NDA approval, generic drug ANDA pathway, OTC monograph system, drug establishment registration, annual fees, SPL drug listing, NDC numbers, cGMP requirements, labeling rules, and post-market obligations. With what every consultant needs to advise pharmaceutical clients correctly.
What Is a Drug Under U.S. Law
Under 21 U.S.C. § 321(g)(1), a drug is defined as any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body. This definition is intentionally broad — it captures prescription medications, over-the-counter products, biologics used as drugs, and even some products that don't look like drugs at all (an article becomes a drug the moment it is intended to treat a disease).
As established in Module 04, intended use determines classification. The same physical substance — say, niacinamide — is an ingredient in countless cosmetics and dietary supplements. The moment a company markets it as a treatment for pellagra (a niacin deficiency disease), that specific product becomes a drug. The molecule didn't change. The intended use did.
No Drug May Be Marketed in the U.S. Without Prior FDA Approval
Unlike food, cosmetics, and dietary supplements — where products can be marketed without pre-market FDA review — every drug must be approved before it enters U.S. commerce. There are no exceptions for "traditional" products, foreign-approved drugs, or products that have been on the market in other countries for decades. An Indian pharmaceutical company whose drug has been approved by the DCGI for 30 years still needs an FDA-approved NDA or ANDA before marketing in the United States. This is non-negotiable and shocks many international pharmaceutical clients.
Drug Establishment Registration — The Annual Obligation
Every establishment that manufactures, repacks, or relabels drugs for the U.S. market must register with CDER annually. This is separate from — and in addition to — any drug application approval. Registration and approval are independent obligations: a facility can be registered but have no approved drugs, or have approved drugs at an unregistered facility (a serious violation).
Drug User Fees — The Financial Reality
User fees are a defining financial reality of the pharmaceutical industry. For international drug manufacturers, the foreign establishment fee is often the first — and largest — surprise when entering the U.S. market. Plan for these in any client engagement.
Fee Schedule Updates Every Fiscal Year (October 1). The figures above are FY2025 approximations. Actual fees change each year based on PDUFA, GDUFA, and MDUFA reauthorization agreements. Always verify current fees at fda.gov/industry/[program]-user-fee-programs before advising any client on drug development budgets. Getting this wrong by even one year can misrepresent project costs by tens of thousands of dollars.
Drug Application Pathways — The Four Routes to Market
Every drug marketed in the United States reaches market through one of four pathways. Knowing which pathway applies — and when each is appropriate — is the core of pharmaceutical regulatory strategy.
- Required for any new drug not previously approved by FDA
- Must demonstrate safety and effectiveness through full clinical trial program (Phases I, II, III)
- Chemistry, Manufacturing, and Controls (CMC) section must demonstrate manufacturing quality and consistency
- Full prescribing information (labeling) reviewed and approved by FDA
- Pre-approval inspection of manufacturing facility by ORA
- Upon approval: market exclusivity granted (5 years for new chemical entity, 3 years for new indication)
- For generic versions of already-approved drugs (Reference Listed Drugs in the Orange Book)
- Must demonstrate pharmaceutical equivalence: same active ingredient, dosage form, strength, route, and labeling
- Bioequivalence studies required — AUC and Cmax must be within 80–125% of RLD
- No need to repeat clinical safety/efficacy trials — relies on innovator's clinical data
- First ANDA filer who certifies against patents (Paragraph IV) gets 180-day market exclusivity
- Pre-approval inspection of manufacturing facility by ORA
- OTC drugs conforming to an FDA monograph can be marketed without an NDA
- Monograph specifies: permitted active ingredients and concentrations, permitted indications, required warnings, label format (Drug Facts panel)
- Updated by the OTC Monograph Reform Act (2020) — now through administrative orders rather than rulemaking
- New OTC ingredients or uses not covered by a monograph require an NDA
- Common monograph categories: analgesics (aspirin, ibuprofen, acetaminophen), antacids, antihistamines, sunscreens, topical antifungals, cough/cold products
- Manufacturer must register establishment and list the drug product
- Required before conducting clinical studies of an unapproved drug in U.S. human subjects
- Not an approval — it is an exemption from the prohibition on shipping unapproved drugs across state lines for clinical use
- FDA has 30 days to place a clinical hold after IND submission; silence means the trial can proceed
- Must include: pre-clinical data, investigator information, protocol, informed consent procedures, and chemistry/manufacturing information
- Annual IND reports required throughout the clinical program
- Emergency IND: FDA can authorize within hours for life-threatening situations
The Full Drug Development Pipeline
For brand-name drugs, the regulatory pathway is embedded in a decade-long development process. Understanding this timeline is essential for advising pharmaceutical clients on realistic expectations — and for understanding why a $4M NDA application fee represents a small fraction of total drug development costs (typically $1–3 billion for a new molecular entity).
Expedited Programs — Faster Pathways for Serious Conditions
FDA has created four special programs to accelerate development and review of drugs for serious or life-threatening conditions. Understanding these programs helps consultants advise clients on whether their drug qualifies for an expedited pathway — which can significantly change the development economics.
| Program | Who Qualifies | Key Benefit | When to Request |
|---|---|---|---|
| Fast Track | Drugs treating serious conditions with unmet medical need | Rolling review — FDA reviews completed sections of the NDA as they're submitted, rather than waiting for the complete package. More frequent FDA meetings. | During clinical development, before NDA submission. Can request at any time after IND filing. |
| Breakthrough Therapy | Preliminary clinical evidence shows substantial improvement over existing therapy on a clinically significant endpoint | Intensive FDA guidance beginning in Phase I; organizational commitment of senior FDA staff; rolling review. Most valuable designation — essentially a partnership with FDA. | After early clinical evidence (often Phase I/II data). Request in writing with clinical data. |
| Accelerated Approval | Drugs for serious conditions using a surrogate or intermediate endpoint reasonably likely to predict clinical benefit | Market approval based on surrogate endpoint (e.g., tumor shrinkage instead of survival). Post-market confirmatory trials required to verify predicted clinical benefit. | When direct clinical benefit endpoint would take many years to measure; common in oncology. |
| Priority Review | Drugs offering major advance in treatment or providing therapy where none exists | 6-month review clock instead of 10 months. Assigned at NDA filing. Does not change what FDA requires — just how fast they review it. | Requested at NDA submission. FDA determines eligibility and notifies applicant within 60 days of receipt. |
Orphan Drug Designation (not an accelerated pathway but equally important): For drugs treating rare diseases affecting fewer than 200,000 U.S. patients. Benefits include 7-year market exclusivity, 50% tax credit on qualified clinical trial expenses, waiver of NDA application fee, and enhanced FDA interactions. Request from OOPD (Office of Orphan Products Development) at any stage of development — ideally before Phase III.
Generic Drugs — The ANDA System in Depth
Generic drugs represent approximately 90% of all prescriptions dispensed in the United States. Understanding the ANDA system is critical for consultants working with international pharmaceutical manufacturers — many of the world's largest generic drug producers are in India, China, and other countries that represent a major portion of Regovant's potential client base.
The Bioequivalence Standard
The foundational requirement for generic drug approval is bioequivalence — demonstrating that the generic drug performs in the body in the same way as the Reference Listed Drug (RLD). FDA's standard: the 90% confidence interval for AUC and Cmax ratios must fall within 80–125% of the RLD values.
The Orange Book — Every Generic's Starting Point
FDA's Approved Drug Products with Therapeutic Equivalence Evaluations — known universally as the Orange Book — lists every approved prescription drug and its therapeutic equivalence rating. Every ANDA must identify its RLD from the Orange Book. The Orange Book also lists patents associated with each drug, which determines the Paragraph certification strategy.
| Paragraph Certification | What It Means | Consequence |
|---|---|---|
| Paragraph I | No patents listed for the RLD in the Orange Book | No patent issues — ANDA can proceed immediately |
| Paragraph II | Patents listed have expired | No patent issues — ANDA can proceed immediately |
| Paragraph III | ANDA applicant will wait for patent expiration before marketing | Approval granted but marketing held until patent expires |
| Paragraph IV | ANDA applicant certifies the listed patent is invalid or not infringed | Must notify patent holder → 45-day window for patent holder to sue → 30-month stay of ANDA approval while litigation proceeds → First Para. IV filer wins 180-day exclusivity if successful |
Pre-Approval Inspections (PAI) for Generics
Before FDA approves an ANDA, ORA conducts a Pre-Approval Inspection (PAI) of the manufacturing facility. The PAI assesses whether the facility's manufacturing process matches what was described in the ANDA, and whether the facility is in cGMP compliance. A PAI failure — even for a minor cGMP deficiency — can delay ANDA approval by 12–24 months. For foreign generic manufacturers, PAI scheduling is often the longest variable in the approval timeline.
Data Integrity — The #1 Reason for Generic Drug Import Alerts Against Indian Facilities: FDA has placed dozens of Indian generic drug facilities on import alert for data integrity failures — falsified analytical records, backdated entries, deleted chromatography data. Under 21 CFR Part 211, all data must be original, accurate, complete, and attributable to the person who collected it. Data integrity issues are treated as fraud, not merely as cGMP violations, and carry criminal referral potential.
The OTC Monograph System — In Detail
Hundreds of common OTC drugs can be marketed without an NDA by conforming to FDA's published monographs. The monograph system is powerful for international manufacturers who want to market OTC products in the U.S. without the cost of a full NDA — as long as their product exactly conforms to the monograph's requirements.
What a Monograph Contains
- Category conditions: The disease or condition the OTC drug may be used to treat
- Permitted active ingredients: Specific chemical entities with concentration ranges (e.g., aspirin 325mg–650mg per dose for pain relief)
- Labeling requirements: Exact Drug Facts panel content including permitted uses, required warnings, and dosing directions
- Testing standards: Dissolution, assay, and quality specifications
- Prohibited combinations: Which active ingredients cannot be combined
Common OTC Monograph Categories
OTC Monograph Reform Act (2020): The Coronavirus Aid, Relief, and Economic Security (CARES) Act included the OMRA, which fundamentally changed the OTC monograph system. Previously, changes to monographs required formal rulemaking (taking 10+ years). Under the OMRA, FDA now uses administrative orders — a much faster process. This has significant implications: FDA can now add, update, or withdraw OTC conditions far more quickly than before.
Drug Listing — The Product-Level Obligation
Separate from establishment registration, every drug product marketed in the U.S. must be individually listed with FDA. Drug listing is done through the same SPL XML system as establishment registration, but captures product-specific information rather than facility information.
What Drug Listing Requires
- NDC Number — National Drug Code, assigned by the labeler; unique to each product-package combination
- Drug labeling — The full, current labeling in SPL format (for prescription drugs: the Prescribing Information; for OTC: the Drug Facts panel)
- Active and inactive ingredients with quantities per dosage unit
- Dosage form and route of administration
- Product type (prescription, OTC, homeopathic)
- Marketing status — whether the product is currently being marketed
The NDC Number — Understanding the Structure
NDC numbers appear on all drug labels and cartons, in all drug listing submissions, on insurance claims, in pharmacy dispensing records, and in adverse event reports. They are the universal identifier linking a drug product to its manufacturer and its FDA listing. A drug marketed without an NDC number on its label is misbranded under 21 CFR § 201.2.
cGMP for Human Drugs — The Manufacturing Standard
Every drug manufacturer must comply with current Good Manufacturing Practice regulations — the legal minimum quality standards for drug production. The primary cGMP regulations for finished pharmaceutical products are found in 21 CFR Part 211, with general provisions in 21 CFR Part 210.
Every Record Must Be Attributable, Legible, Contemporaneous, Original, and Accurate
ALCOA+ is the gold standard for pharmaceutical record-keeping, derived from FDA and ICH guidance on data integrity. "+" adds: Complete, Consistent, Enduring, and Available. FDA inspectors specifically look for ALCOA+ compliance during cGMP inspections:
- Attributable: Every entry signed/initialed with date and time by the person who performed it
- Legible: Readable — no overwritten entries; corrections made with single line through error, initialed
- Contemporaneous: Recorded at the time the activity is performed — not reconstructed from memory later
- Original: First record of data — not a copy, transcription, or reconstruction
- Accurate: True, correct, and free from errors — including electronic data (no deleted/overwritten audit trails)
Drug Labeling Requirements
Drug labeling is among the most precisely regulated content in any industry. Every word is reviewed by FDA. Every format element is specified in regulation. Labeling violations are among the most common reasons for FDA enforcement action against pharmaceutical products.
Prescription Drug Labeling — Full Prescribing Information (21 CFR § 201.56–57)
Prescription drug labeling (the "package insert" or PI) follows a highly specific format with content regulated by 21 CFR § 201.56 and § 201.57. All drugs approved after June 30, 2006 must use the "Physician Labeling Rule" (PLR) format with a Highlights section.
OTC Drug Facts Panel — Format and Content (21 CFR § 201.66)
Every OTC drug must have a Drug Facts panel in a specific format with sections in a mandatory order. The format is designed so any consumer can quickly find safety information.
Required Drug Label Elements Beyond Labeling Content
| Required Element | Regulation | Detail |
|---|---|---|
| NDC Number | 21 CFR § 201.2 | Must appear on all labels and cartons. Format: XXXXX-XXXX-XX or XXXXX-XXX-XX. Barcode encoding required for most drugs. |
| "Rx Only" symbol | 21 CFR § 201.100 | Required on all prescription drug labeling. Must be prominent on principal display panel. No prescription drug may be dispensed without a valid prescription. |
| Controlled Substance Schedule | 21 CFR § 1302.06 | Schedule II–V must be labeled with the DEA schedule (e.g., "Schedule II Controlled Substance" or "CII"). Also requires special DEA registration for the manufacturer. |
| Established Name | 21 CFR § 201.10 | Generic/established name must appear prominently and conspicuously on all labels. Must be at least half the type size of any proprietary (trade) name. |
| Quantity/Net Contents | 21 CFR § 201.51 | Number of dosage units or weight/volume of drug in the package. For oral solids: tablet/capsule count. For liquids: volume in milliliters. |
| Manufacturer Name & Address | 21 CFR § 201.1 | Name and address of manufacturer, packer, or distributor. Must be complete — city, state/country, postal code. |
Post-Market Obligations — The Approval Isn't the End
FDA approval is not the end of a drug's regulatory life — it's the beginning of post-market obligations that continue indefinitely. Many pharmaceutical clients are surprised to learn that post-market compliance can be as demanding as the pre-approval process.
Importing Drugs into the U.S. — Special Considerations
While food imports require Prior Notice for every shipment, drug imports have a different screening mechanism. FDA uses the Drug Registration and Listing System (DRLS) to verify that imported drugs come from registered facilities — and checks whether those facilities have approved applications.
| Scenario | What Happens at the Border | Action Required |
|---|---|---|
| Approved drug from registered facility | Normal CBP entry process. FDA screens using PREDICT. Most shipments pass automatically. | Ensure facility registration is current and annual fee paid. Keep drug listing updated. |
| Drug from unregistered facility | Shipment flagged as adulterated under 21 U.S.C. § 351(a)(2)(B). Import alert potential. | Register facility before first shipment. Pay annual establishment fee. |
| Unapproved drug (no NDA/ANDA) | Refused as an unapproved new drug under 21 U.S.C. § 355. Cannot enter U.S. commerce under any circumstances. | Obtain approval through NDA, ANDA, or confirm it meets an OTC monograph before attempting import. |
| Drug on Import Alert (IA 66-40) | Detained without physical examination. All shipments from the listed facility automatically refused. | Remediation plan required. Facility must demonstrate cGMP compliance and resolve all Warning Letter issues before removal from IA. |
| Personal imports (small quantities) | FDA exercises enforcement discretion for personal use quantities (typically 90-day supply). Not for commercial import. | For commercial drug import, no exceptions to approval requirement exist. |
Everything That Needs to Happen Before the First Tablet Ships
An Indian generic pharmaceutical manufacturer in Hyderabad has been producing metformin tablets for the Indian and European markets for 15 years. Their U.S. distribution partner tells them they need to start exporting to the U.S. Here is the complete regulatory sequence:
- Step 1 — Choose the RLD: Identify the Reference Listed Drug for metformin in the Orange Book (FDA Orange Book Product Search). Confirm the patent status and determine the Paragraph certification strategy.
- Step 2 — Facility Registration: Register the manufacturing facility with CDER via the SPL system. Obtain a Drug Establishment Identifier (DEI). Pay the foreign drug establishment fee (~$75,000 for the first year under GDUFA).
- Step 3 — Conduct Bioequivalence Studies: Commission bioequivalence studies in U.S.-compliant clinical facilities demonstrating that the metformin tablet is bioequivalent to the RLD. AUC and Cmax within 80–125% confidence interval. This typically costs $500K–$2M and takes 12–18 months.
- Step 4 — Prepare and Submit ANDA: Prepare the Abbreviated New Drug Application including all BE data, CMC sections, labeling, and Paragraph certification. Submit to CDER's Office of Generic Drugs. Pay the ANDA application fee (~$220,000). Current review time: approximately 30 months.
- Step 5 — Pre-Approval Inspection: ORA will schedule a PAI of the Hyderabad facility. Ensure the facility is in cGMP compliance under 21 CFR Parts 210/211. ALCOA+ data integrity standards must be demonstrable. Any data integrity deficiency delays approval by 12–24 months.
- Step 6 — Respond to FDA Deficiency Letters: FDA will almost certainly issue one or more deficiency letters (Complete Response Letters) requesting additional data or labeling clarifications. Typical ANDA goes through 1–3 amendment cycles before approval.
- Step 7 — ANDA Approval and Drug Listing: Upon approval, the NDC number is finalized and the drug listing is updated to reflect marketed status. The first shipment can then enter the U.S. legally.
- Every drug marketed in the U.S. requires FDA approval before commerce — no exceptions for traditional products, foreign approvals, or long market history. An NDA (brand-name), ANDA (generic), or OTC monograph conformance is required for every drug product.
- Drug establishment registration is annual (Oct–Dec each year) and carries significant fees — approximately $75,000/year for foreign manufacturers under GDUFA. Missing renewal triggers automatic adulteration of all products from that facility and can halt ANDA review.
- The NDA pathway requires full clinical trials (Phases I, II, III) — a 10–15 year, $1–3 billion process. Four expedited programs exist for serious conditions: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. Knowing when to request each is core pharmaceutical regulatory strategy.
- The ANDA pathway for generics requires bioequivalence studies (AUC and Cmax within 80–125% of RLD) but no full clinical trials. Review time averages ~30 months. Paragraph IV certification enables patent challenges and 180-day generic market exclusivity for first filers.
- Every marketed drug must be listed with FDA via the SPL system, including a National Drug Code (NDC) number. The NDC format is [Labeler Code]-[Product Code]-[Package Code]. Missing NDC on a drug label = misbranding. Labeling violations in the drug category are treated with high severity by FDA.
- cGMP under 21 CFR Parts 210/211 requires comprehensive written procedures, quality control unit independence, batch manufacturing records, and ALCOA+ data integrity. Data integrity failures — the leading cause of import alerts against Indian generic manufacturers — are treated as fraud, not mere quality deficiencies.
- Post-market obligations are permanent: adverse event reporting within 15 days, annual reports, prior approval supplements for major changes, and REMS compliance for restricted drugs. Approval is the beginning of the regulatory relationship, not the end.
Need guidance on pharmaceutical regulatory strategy?
Regovant supports drug establishment registration, facility fee management, drug listing via SPL, labeling reviews, and pre-submission strategy for international pharmaceutical manufacturers entering the U.S. market.